Mark Diker Insider Sell
director, Mark Diker is the Cantel Medical Corp’s insider which sold shares of Cantel Medical Corp, 10,000 to be exact. The mentioned shares were based on $56.6, with the deal having an approx. value of $566,440 U.S. Dollars. Presently, Mark Diker owns 494,395 shares which are about 1.19% of Cantel Medical Corp’s market capitalization.
Cantel Medical Corp Sentiment and Fundamentals
Data from the two leading security analysts who cover Cantel Medical Corp’s stock see the price-earnings ratio to be 39.38 if the EPS in 2015 is $1.43 per share.
Over the last 200 days Cantel Medical Corp’s share price has climbed 35.26% and presently is in smooth uptrend. OctaFinance’s trend system, coupled with Mark’s new stock trade, gives us no choice but to rate the stock “NEUTRAL”.
As Felix Zulauf, a money-making machine, noted, that the best returns are made through a combination of technical & fundamental analysis.” This is definitely not the case with Cantel Medical Corp’s stock.
Institutional Ownership
Data gathered from 13F SEC filings, show that 158 hedge funds and institutional investors have shares of Cantel Medical Corp. The institutional ownership of this company in the last quarter is high, at 81.98% of the shares outstanding. They increased by 307,965 the total shares they hold. As of that quarter these hedge funds owned 34.11 million shares. A total of 19 funds closed their positions in Cantel Medical Corp and 56 reduced their holdings. There were 13 funds that created new positions and 59 funds that added to their positions.
There are six registered investment managers having this stock in their Top 10. Some of them are: Brown Capital Management Llc, Diker Management Llc, Teton Advisors Inc., Conestoga Capital Advisors Llc, Kimelman & Baird Llc, Geller Family Office Services Llc.
Brown Capital Management Llc is the most bullish institutional investor on Cantel Medical Corp, with ownership of 5.62 million shares as of Q2 2015 for 4.96% of the fund’s portfolio. Mark N. Diker’s Diker Management Llc is another bullish institutional manager having 2.05 million shares of the company or 19.24% of their stocks portfolio. The stock is also 16.28% of the fund’s AUM. Moreover The New York-based fund Teton Advisors Inc. have 1.94% of their stock portfolio invested in the stock for 528,005 shares. Conestoga Capital Advisors Llc disclosed it had purchased a stake worth 3.65% of the fund’s stock portfolio in Cantel Medical Corp. Kimelman & Baird Llc is also positive in the stock, owning 474,285 shares or 4.34% of their stock portfolio.
Cantel Medical Corp NYSE:CMN Company Profile
Cantel Medical Corp is a provider of infection prevention and control products and services. Cantel operates in five segments. Endoscopy includes medical device reprocessing systems, disinfectants, detergents and other supplies used to disinfect flexible endoscopes. Water Purification and Filtration includes water purification equipment and services, filtration and separation products and disinfectants. Healthcare Disposables includes infection prevention and control products. Dialysis includes medical device reprocessing systems, sterilants, dialysate concentrates and other supplies for renal dialysis. Specialty Packaging includes specialty packaging and thermal control products, and related compliance training for the transport of infectious and biological specimens and thermally sensitive pharmaceutical, medical and other products.
Company Website: Cantel Medical Corp
Cantel Medical Corp was founded in Delaware on 1963-08-16. As of writing its market worth is: $2.33 billion and it has 41.67 million outstanding shares. Cantel Medical Corp has 1680 employees. As of writing the company has 84.66% shareholders and the institutional ownership stands at 84.66%. The stock closed at $56.119999 yesterday and it had average 2 days volume of 41442 shares. It is down from the 30 days average shares volume of 42906. Cantel Medical Corp has a 250 days low of $35.21 and a 250 days high of $58.00. The stock price is above the 200 days SMA. Cantel Medical Corp last issued its quarterly earnings data on 09/29/2015. The company reported 0.39 EPS for the quarter, above the consensus estimate of 0.3 by 0.09. The company had a revenue of 151.26 million for 7/31/2015 and 141.51 million for 4/30/2015. Therefore, the revenue was 9.75 million up.
* The per share sale prices ranged from $56.4794 to $56.90. Upon request by the Commission staff - the issuer or the reporting person will provide full information regarding the number of shares sold at each separate price.
